A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety (Q35737846)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 2004

Language	Label	Description	Also known as
English	A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety	scientific article published on March 2004

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety (English)

1 reference

Europe PubMed Central

10 August 2017

1 reference

based on heuristic

inferred from title

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

based on heuristic

inferred from title

Myron M. Levine

16

object named as

Myron M Levine

1 reference

Europe PubMed Central

10 August 2017

4

object named as

Leif Gothefors

1 reference

Europe PubMed Central

10 August 2017

author name string

Eric Mallet

1

1 reference

Europe PubMed Central

10 August 2017

Bernd H Belohradsky

2

1 reference

Europe PubMed Central

10 August 2017

Rosanna Lagos

3

1 reference

Europe PubMed Central

10 August 2017

Patrice Camier

5

1 reference

Europe PubMed Central

10 August 2017

Jean-Pierre Carrière

6

1 reference

Europe PubMed Central

10 August 2017

Güler Kanra

7

1 reference

Europe PubMed Central

10 August 2017

Agnès Hoffenbach

8

1 reference

Europe PubMed Central

10 August 2017

Jacques Langue

9

1 reference

Europe PubMed Central

10 August 2017

François Undreiner

10

1 reference

Europe PubMed Central

10 August 2017

François Roussel

11

1 reference

Europe PubMed Central

10 August 2017

Philippe Reinert

12

1 reference

Europe PubMed Central

10 August 2017

Carl-Erik Flodmark

13

1 reference

Europe PubMed Central

10 August 2017

Silvia Stojanov

14

1 reference

Europe PubMed Central

10 August 2017

Johannes Liese

15

1 reference

Europe PubMed Central

10 August 2017

Alma Muñoz

17

1 reference

Europe PubMed Central

10 August 2017

Florian Schödel

18

1 reference

Europe PubMed Central

10 August 2017

Luc Hessel

19

1 reference

Europe PubMed Central

10 August 2017

Hexavalent Vaccine Trial Study Group

20

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

10 August 2017

number of pages

15

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

10 August 2017

22

1 reference

Europe PubMed Central

10 August 2017

11-12

1 reference

Europe PubMed Central

10 August 2017

1343-1357

1 reference

Europe PubMed Central

10 August 2017

Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Are different combined vaccines needed in different parts of Europe? A point of view from a northern-European country

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Epidemiological views into possible components of paediatric combined vaccines in 2015.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Efficacy of a two-component acellular pertussis vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

The acellular pertussis vaccine trials: an interpretation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Inactivated polio vaccine for the United States: a missed vaccination opportunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Haemophilus influenzae type b disease and vaccination in Europe: lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Epidemiology of hepatitis B

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-mont

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Immunological response to conjugate vaccines in infants: follow up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Anti-HBs and immunological memory to HBV vaccine: implication for booster timing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Very low dose hepatitis B vaccination in the newborn: anamnestic response to booster at four years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

What level of hepatitis B antibody is protective?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Acellular pertussis vaccines: new vaccines for an old disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

A placebo-controlled trial of a pertussis-toxoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.039

7 January 2021

Identifiers

10.1016/J.VACCINE.2003.09.039

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35737846&oldid=2080259348"